Lynx1 Capital Management LP
Sector Allocation
- Healthcare100.0%$507.6M
AUM History
13fpro.ai/research/fund/lynx1-capital-management-lp-1910456
Conviction and streaks
Concentrating · top 10 = 98.7%From the fund's last 12 quarters of 13F filings: positions held longest at size, and names it added to or trimmed several quarters running.
Largest positions — Q2 2026
CGEM
$163.2MSTOK
$132.1MAGIO
$126.5MCCCC
$34.2MKRRO
$20.3MTCRX
$7.9MDTIL
$7.5MNEUP
$3.8MPASG
$3.3MCGON
$2.2MPLRX
$2.0MTRDA
$1.3MYARW
$1.1MTRAW
$472KFHTX
$301KDNLI
$300KXNCR
$293KHOWL
$237KAVTX
$187KBOLT
$119K
Top 20 stock positions. Options are left out: 13F reports them at the underlying's value.
13fpro.ai/research/fund/lynx1-capital-management-lp-1910456
Lynx1 Capital Management LP 13F holdings — Q2 2026
$507.6M portfolio (-19.8% QoQ) · 23 holdings · Q2 2026 13F · top 10 are 99% of the stock portfolio
$163.2M
32.2% of stocks
No changeThis quarter-25.8%Since filed9 qtrsHeld$132.1M
26.0% of stocks
-15%This quarter-22.8%Since filed10+ qtrsHeldAIQuality25.0#2,640Est. buyEstimated buy price is Pro: unlock with a free trialTrimmed 2 qtrs in a row$126.5M
24.9% of stocks
+31%This quarter+7.7%Since filed3 qtrsHeldAIQuality26.7#2,578Est. buyEstimated buy price is Pro: unlock with a free trialAdded 3 qtrs in a row$34.2M
6.7% of stocks
+5%This quarter-23.6%Since filed10+ qtrsHeld$20.3M
4.0% of stocks
No changeThis quarter-10.0%Since filed3 qtrsHeld$7.9M
1.6% of stocks
No changeThis quarter-75.5%Since filed10+ qtrsHeld$7.5M
1.5% of stocks
-4%This quarter-13.6%Since filed7 qtrsHeld$3.8M
0.8% of stocks
No changeThis quarter-11.3%Since filed3 qtrsHeld$3.3M
0.7% of stocks
+8%This quarter-26.8%Since filed10+ qtrsHeld$2.2M
0.4% of stocks
-0.6%This quarter-20.0%Since filed3 qtrsHeld
All holdings — Lynx1 Capital Management LP (Q2 2026)
23 disclosed positions from the Form 13F-HR on SEC EDGAR, with quarter-over-quarter share changes. Largest by value first; the ten above are not repeated.
| # | Company | Held | Source | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 11 | PLIANT THERAPEUTICS, INC. | Healthcare | $2.0M | 0.4% | 1.80M | New | 1 qtr | AI quality score is Pro: unlock with a free trial | 13F | |
| 12 | Entrada Therapeutics, Inc. | Healthcare | $1.3M | 0.3% | 179K | -16% | 3 qtrs | AI quality score is Pro: unlock with a free trial | 13F | |
| 13 | Yarrow Bioscience, Inc. | Healthcare | $1.1M | 0.2% | 1.63M | — | 2 qtrs | AI quality score is Pro: unlock with a free trial | 13F | |
| 14 | Traws Pharma, Inc. | Healthcare | $472K | 0.1% | 559K | +3611% | 2 qtrsAdded 2 qtrs in a row | AI quality score is Pro: unlock with a free trial | 13F | |
| 15 | Foghorn Therapeutics Inc. | Healthcare | $301K | 0.1% | 62K | New | 1 qtr | AI quality score is Pro: unlock with a free trial | 13F | |
| 16 | Denali Therapeutics Inc. | Healthcare | $300K | 0.1% | 12K | -99% | 4 qtrs | AI quality score is Pro: unlock with a free trial | 13F | |
| 17 | Xencor Inc | Healthcare | $293K | 0.1% | 18K | -97% | 3 qtrsTrimmed 2 qtrs in a row | AI quality score is Pro: unlock with a free trial | 13F | |
| 18 | Werewolf Therapeutics, Inc. | Healthcare | $237K | 0.1% | 658K | — | 3 qtrs | AI quality score is Pro: unlock with a free trial | 13F | |
| 19 | Avalo Therapeutics, Inc. | Healthcare | $187K | 0.0% | 10K | New | 1 qtr | AI quality score is Pro: unlock with a free trial | 13F | |
| 20 | Bolt Biotherapeutics, Inc. | Healthcare | $119K | 0.0% | 31K | — | 2 qtrs | AI quality score is Pro: unlock with a free trial | 13F | |
| 21 | Nuvation Bio Inc. | Healthcare | $91K | 0.0% | 16K | New | 1 qtr | AI quality score is Pro: unlock with a free trial | 13F | |
| 22 | EUPRAXIA PHARMACEUTICALS INC. | Healthcare | $66K | 0.0% | 10K | New | 1 qtr | AI quality score is Pro: unlock with a free trial | 13F | |
| 23 | Inhibikase Therapeutics, Inc. | Healthcare | $41K | 0.0% | 20K | New | 1 qtr | AI quality score is Pro: unlock with a free trial | 13F |
What changed in Q2 2026
Against the previous quarter's 13F: 6 new, 4 added to, 6 trimmed, 6 sold out. Share-count changes; largest moves by dollar size first.
New positions (6)
first bought this quarter
first bought this quarter
first bought this quarter
$NUVBNuvation Bio Inc.$91K
first bought this quarter
$EPRXEUPRAXIA PHARMACEUTICALS INC.$66K
first bought this quarter
$IKTInhibikase Therapeutics, Inc.$41K
first bought this quarter
Added to (4)
Trimmed (6)
now $300K · held 4 qtrs
now $132.1M · held 10+ qtrs, 2 trims in a row
now $293K · held 3 qtrs, 2 trims in a row
now $7.5M · held 7 qtrs
now $1.3M · held 3 qtrs
now $2.2M · held 3 qtrs
Holdings by quarter
Every 13F Lynx1 Capital Management LP has filed, 18 earlier quarters. Pick one to see what it held then.
Is it too late to follow Lynx1 Capital Management?
Q2 2026 13F filed with the SEC on Aug 12, 2026. Prices are closing prices as of Oct 26, 2026.
Average quality of Lynx1 Capital Management's top 20 holdings: 25/100 (our AI quality score, weighted by position size; 11 of the 20 are scored)
Top 10 since filing
-16.2%
Value-weighted move of the 10 largest stock positions
Turnover
6%
Last quarter; 40% over the last 4
Top 10 weight
99%
Share of the stock portfolio in its 10 largest positions
Held 4+ quarters
69%
Share of portfolio value in positions held a year or more
Highest-quality names it owns(among its 100 largest positions)
The 8 highest-scoring companies in this portfolio are a Pro feature.
How these are measured
- Moves since the quarter-end and since the filing date use our own daily closing prices, from the close on (or just before) each date to the latest close.
- Turnover is the lesser of shares bought or sold in a quarter, valued at the quarter-end prices in the 13F, divided by the average of the two quarters' stock portfolio values.
- Quarters held and add/trim streaks count back only through quarters whose filed holdings add up to the filing's own cover-page total (back to Q1 2024 for this fund). A change counts as an add or a trim when the split-adjusted share count moves by more than 1%.
- Estimate, not the fund's reported cost. For each quarter in the current holding period in which the fund's share count rose (split-adjusted), we take that quarter's average daily close and weight it by the shares added; sales do not change an average cost. Quarters where the stock's price history and the 13F's own implied price disagree by more than 2x are left out.
- Put and call option rows report the value of the underlying shares, not a position the fund paid for, so they are left out of all of the above.
Portfolio Overview
Lynx1 Capital Management LP disclosed 23 positions worth $507.6M in its Form 13F-HR for Q2 2026, led by $CGEM (Cullinan Therapeutics, Inc.) at 32.2% of the equity portfolio, followed by $STOK and $AGIO. During the quarter the fund opened 6 new positions and exited 6 — including a new stake in $PLRX and a full exit from $GHRS. The portfolio is most concentrated in Healthcare (100.0% of disclosed assets). All figures are sourced directly from Lynx1 Capital Management LP’s Form 13F-HR filing with the SEC under CIK 1910456.
Funds like this
managers whose biggest positions overlap Lynx1 Capital Management'sBrowse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
AI-Powered Hedge Fund Analysis: Lynx1 Capital Management LP
13F Pro is an AI hedge fund tracker and stock research platform. For Lynx1 Capital Management LP (SEC CIK: 1910456), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in Lynx1 Capital Management LP's portfolio is scored on an AI quality ranking built from its SEC filings (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.